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Abstract 
 
Prostate cancer is the most common form of cancer amongst males in the western 
world. Today’s diagnostic methods for prostate cancer that rely on PSA measurement 
are not satisfying. The level of prostate specific antigen (PSA) is determined in a blood 
test. Of the men with elevated PSA levels only 25 % have prostate cancer. This thesis 
aims to develop a proof of concept for a miniaturized multiplex microarray, which in a 
future perspective could be used as a diagnostic tool for prostate cancer. Different 
diagnostic methods are used today but none are separately sufficiently specific. The 
microarray based method in this thesis aims to a screening technique for simultaneous 
measurements of total, free and intact PSA as well as free human kallikrein 2 (hK2) in 
serum. The intermediate goal was a dual approach where PSA total and free are 
measured on two chips. The dual assay paved the way to the multiplex approach where 
different biomarkers simultaneously were measured on the same porous silicon chip. In 
both approaches a capture antibody was dispensed onto a porous surface. The chip was 
incubated with the biological sample and detected with a fluorescently labeled detector 
antibody in a confocal microscope. The intermediate dual assay was validated using 8 
plasma samples obtained from the clinical routine analysis. Furthermore, three 
biomarkers (PSA total, free and intact) were successfully detected simultaneously on a 
porous silicon chip sized 3.5 x 3.5 mm.  
 
 
 2 
Contents 
 
Abbreviations 3 
1. Background and Methodology 4 
1.1 Prostate Disease 4 
1.2 Prostate Specific Antigen 4 
1.3 Proteomics 6 
1.4 Protein Chip Technology 7 
1.5 Surfaces within Protein Chip Technology 9 
1.6 Micro- and Nanoporous Silicon 9 
1.7 Microdispenser 11 
1.8 Streptavidin Alexa Fluor 488 and FITC-labeled Antibodies 11 
1.9 Epitope Map 12 
1.10 Aims 12 
2. Materials and Methods 13 
2.1 Materials, Reagents and Proteins 13 
2.2 Samples from the Clinical Routine 13 
2.3 Fabrication of Nanoporous Silicon Chip 13 
2.4 Dialysis 13 
2.5 Biotinylation 14 
2.6 Dual Assay 14 
2.7 Multiplex Assay 14 
2.8 Mean Spot Intensity (MSI) and Limit of Detection (LOD) 15 
2.9 DELFIA 15 
3. Results and Discussion 16 
3.1 Assay Development 16 
3.1.1 Dispenser and Etching 16 
3.1.2 Blocking 17 
3.1.3 Background 17 
3.1.4 Spot Focus 18 
3.2 Dual Assay 18 
3.3 Multiplex Assay 20 
3.3.1 Total PSA 21 
3.3.2 Free PSA 22 
3.3.3 Intact PSA 23 
3.3.4 hK2 free 24 
3.3.5 Triplex 25 
4. Conclusions and Further Research 28 
5. Populärvetenskaplig sammanfattning på svenska 29 
6. Acknowledgements 30 
7. References 31 
 
 3 
Abbreviations 
 
11B6 An antibody against hK2 
2E9 An antibody against PSA 
4D4 An antibody against PSA 
5A10 An antibody against PSA 
ab Antibody 
Alexa 488 Alexa Fluor 488 
BPH Benign Prostatic Hyperplasia  
cDNA Complementary Deoxyribonucleic Acid 
CV Coefficient of Variation 
DELFIA Dissociation-Enhanced Lanthanide Fluorescent Immunoassay 
DMF Dimethyl Formamide 
DMSO  Dimethyl Sulfoxide 
EDTA Ethylenedinitrilotetraacetic acid 
F(ab)2 Fragment of the antibody 
Fc Fragment of the antibody 
FITC Fluorescein Isothiocyanate 
H117  An antibody against PSA 
H117-biotin Biotinylated H117 
H50 An antibody against PSA 
HF Hydrofluoric Acid 
hK2 Human kallikrein 2 
HPR Human Proteome Resource 
HRP  Horseradish peroxidase 
HUGO Human Genome Organization 
HUPO  Human Proteome Organisation 
KTH KTH Royal Institute of Technology 
mAb Monoclonal Antibody 
mRNA Messenger Ribonucleic Acid 
MSI Mean Spot Intensity 
MQ MilliQ 
MWCO Molecular Weight Cut Off 
PBS Phosphate buffered saline 
PBST Phosphate buffered saline with Tween 
PCa Prostate Cancer  
PGP Personal Genome Project 
PMT Photomultiplier  
RIA Radioimmunoassay 
RNA Ribonucleic acid 
PSA Prostate Specific Antigen 
RT Room Temperature 
SA Streptavidin 
UMAS Malmö University Hospital 
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1. Background and Methodology  
 
1.1 Prostate Disease 
Prostate cancer is the most common form of cancer and cause of death among men in 
the Western world. The disease is age related and three-quarters of the cases affects men 
aged 65 or above. [1] To diagnose prostate cancer today rectal palpation, transrectal 
ultrasound examination and a blood test to determine the prostate specific antigen (PSA) 
content are used. Each of those three separated methods has only 25-35 % chance of 
finding prostate cancer. [2] In all three methods combined the chance is 60 %. 
Furthermore only 25 % of those with slightly elevated PSA levels have prostate cancer. 
[3] 
 
Instead of prostate cancer, a large part of the patients with elevated PSA have a benign 
prostatic hyperplasia (BPH). BPH is an enlargement of the prostate gland which is not 
considered a premalignant lesion. [4] The prostate grows with age and when the outer 
tissue of the prostate stops expanding, it can lead to compression of the urethral canal. 
The proliferation leads to an elevated PSA concentration in the serum. Infection can 
also cause temporarily elevated PSA level. The prostate have three different zones; 
central, transition and peripheral zone, see Figure 1. BPH often starts in the transition 
zone of the prostate and prostate cancer in the peripheral zone.  
 
 
 
Figure 1 The prostate gland and its three zones, central transition and peripheral zone. [5]  
 
1.2 Prostate Specific Antigen 
Prostate specific antigen is a protein which can be detected in blood samples. PSA is 
secreted by the epithelial cells of the prostate gland. Its function is to break down the 
gelatin-like substance that holds the spermatozoa, such that the sperm can swim more 
easily through the cervix and fertilize the egg. The PSA is transported from the 
sectretory epithelial cells into the lumen, i.e. the sack-like structure of the prostate, in 
the form of proPSA. In lumen proPSA changes to active PSA, that later can be changed 
into inactive forms (Figure 2). It is likely that human kallikrein 2 (hK2) is the 
physiological activator of proPSA. [6] hK2 also belongs to the protein family of human 
kallikreins and corresponds to 10-50 % of the PSA expression. In addition PSA and 
hK2 are expressed extraprostatic in tissues and fluids.  
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The epithelium of the prostate gland is built up by a membrane, basal cells and secretory 
epithelium, see Figure 2. Both active and inactive PSA can leak though the epithelium 
into the blood circulation where it is found in the form of bound and free PSA. PSA in 
serum can be nicked and is then a part of the free PSA. Intact PSA is found in both the 
free and bound form in blood serum. The cells which form the blood-luminal barrier 
with its tight junctions are suggested to be the basal cells. [4] It is believed that prostate 
epithelial stem cells are found in the basal layer.  
 
 
 
Figure 2 Structure of the prostate epithelium [7] 
  
A small part of the PSA leaks into the blood vessels in healthy individuals. Malignant 
tissue is more unorganized and the walls between the prostate and the blood vessels can 
be broken. [2] Therefore increased PSA values in the blood are found in prostate cancer 
patients, even though the production of PSA is lower in the cancer cells. [2] The PSA 
concentration in the serum of a healthy person is approximately 0.6 ng/ml and in lumen 
0.6 mg/ml, Figure 2. [7] 
 
There is a grey zone in PSA concentration between men with BPH and prostate cancer, 
see Figure 3. The normal value for BPH is 0-10 ng/ml PSA in the serum whereas for the 
prostate cancer it is often set from 3 to over 100 ng/ml. [2] There is also a risk to have 
prostate cancer with a value below 3 ng/ml. Approximately 25 % of those with PSA 
values in the upper normal range have prostate carcinoma.  
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Figure 3 Present blood sample for PSA concentration in clinical diagnostics in Sweden [2]  
  
 
In 1987 Stamely and co-workers observed that an elevated PSA level in serum 
correlated with prostate cancer (PCa) as well as disease stage. [8] PSA was then 
suggested to be a marker for prostate cancer. Amongst others Lilja reported about PSA 
as a biomarker for PCa and presented in 1987 a molecular cloning of PSA cDNA [9]. 
PSA correlates with both benign and malignant processes in the prostate. [4] There is 
evidence that the ratio between PSA free/total and hK2 are more closely related to 
prostate cancer. [10] Today both PSA total and the ratio PSA free/total are used in the 
clinic according to Liljas findings. 
 
1.3 Proteomics 
Proteome is a complement of proteins encoded from a genome which is expressed and 
modified by a cell, organism or tissue. The term proteomics derives from the two words 
protein and genomics. Marc R Wilkins coined the term in 1994 being a PhD student. 
[11] He is now a professor in Sydney, Australia. Proteomics is the study of proteins, 
particularly structure and functions, in a tissue or cell at a specific time under certain 
conditions. Within proteomics you can separate, identify and characterize proteins. [12] 
 
Just prior to the proteomic era, the genes were studied. HUGO (Human Genome 
Organization) was one of the two organizations sequencing the human genome, 
published in Nature in February 2001. [13] The competitor Craig Venter and his 
company Celera finished at the same time and published in Science February 2001. [14]  
In the early years of 2000 George M. Church invented the Personal Genome Project 
(PGP). [15] A project that aims to develop a database of 100 000 people’s gene 
sequences connected to their medical records. As of today ten people have already been 
screened and at this moment PGP are looking for additional 100 persons to 
incrementally expand the enrolment.  
 
In the proteome field a still growing project called HUPO (Human Proteome 
Organisation) was started in 2001. [16] HUPO aids the development of international 
proteomic initiatives, so that the human diseases can be better understood. In Sweden 
Professor Mattias Uhlén at KTH started the Swedish Human Proteome Resource (HPR) 
program in 2003. [17] The HPR aims to explore the human proteome using antibody 
based proteomic methods. The project combines bioinformatics, proteomics and 
pathology.  
 
Proteins are much more than just the genes. They can fold and modify after translation 
and act in different unexpected ways. For better understanding of the human body and 
to develop new diagnostic tools, we need to look into the proteins. When the proteomic 
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field began around 1994 the initial technique used was two-dimensional gel 
electrophoresis. During the last 10 years the research for novel disease biomarkers has 
revolutionized the development of mass spectrometry techniques as well as protein and 
antibody microarrays.  
 
1.4 Protein Chip Technology 
Protein chips and protein microarrays are used in methods to determine the presence 
and to some extent also the amount of protein in a sample. Protein chips can also be 
used to determine functionality such as phosphorylation. Antibodies are often used to 
bind the protein of interest, and it is then called antibody arrays.  
 
The protein chip has originated from the immunoassay. In 1950 the Radioimmunoassay 
(RIA) was used by Yalow et al to present an immunoassay for plasma insulin in man. 
[18] This method is extremely sensitive and specific but involves radioactive labeling 
which causes radioactive waste and needs of radioactive protection. [19] From the RIA 
the nonradioisotopic labeling substance immunoassays were developed. Immunoassays 
are often carried out many at the same time. In 1991 the 96 well plate or microplate was 
patented by Pfizer and shortly after became commercialized and a standard definition. 
[20, 21]   
 
Instead of working in a 96 well plate the antibody or biological sample can be arrayed 
onto a chip. The volumes can be reduced and numerous tests can be carried out 
simultaneously on the same chip in a high throughput manner. [22]  This was foreseen 
almost 20 years ago by Ekins and co-workers [23, 24], suggesting a miniaturized format 
of the immunoassays to speed up the kinetics and improve the detection limit. 
 
A technique that could be compared to the protein microarrays is the gene expression 
analysis. In this method oligonucleotides are arrayed onto chips. RNA is then isolated 
from a sample, reverse-transcribed into cDNA, labeled and hybridized onto the array. A 
reference sample is treated the same way but with a different label. [25] The result 
reveals the relative level of RNA in the sample compared to the reference. In this way 
expression analysis of malignant and normal PCa cells could be performed.  
 
The breakthrough that gene expression analysis led to also implied the potential of the 
protein chip technology. It should be noted that the level of mRNA not necessarily 
correlates with the final protein level [26-28]. Today protein chip technology is a well 
established technique [29-31], but still more of a challenge than gene expression 
analysis, mainly since proteins, unlike oligonucleotides, have a vast diversity of surface 
characteristics and can be chemically modified by post-translational modifications.  
 
The three common ways of detecting biomarkers on protein chips include:  
1) direct labeling 
2) reverse-phase antibody microarrays  
3) sandwich immunoassays [32]  
 
In the direct labeling technique illustrated in Figure 4 the capture antibody is dispensed 
and the biological sample, already labeled with the fluorophore, incubated on the chip. 
The readout is performed in a florescent microscope. This method has the disadvantage 
of being time consuming and challenging, because the biological sample needs to be 
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labeled. The two other techniques, reverse-phase and sandwich, omit the labeling 
procedure and are therefore better suited for medical diagnostics.  
 
 
Figure 4 Direct labeling technique. Capture antibodies are dispensed onto the surface (1) and subsequent 
blocking and washing is followed by incubation with the fluorescently labeled biological sample (2). 
After another washing step the detection in a fluorescent microscope (3) is carried out. 
 
In reverse-phase antibody microarrays, as shown in Figure 5, the biological sample is 
arrayed onto the surface. For detection fluorescently labeled detector antibodies are 
incubated with the chip that subsequently is evaluated in a microscope. [32] 
 
 
Figure 5 Reverse-phase antibody microarray [32]. Dispensing of the biological sample (1) is followed by 
washing and blocking steps before incubation with labeled detector antibody (2). More washing steps are 
performed and the detection is carried out in a fluorescent microscope (3). 
 
The sandwich immunoassay, or sandwich antibody microarray, illustrated in Figure 6 
has two different antibodies looking like a sandwich with the biological sample in the 
middle. The capture antibodies are dispensed onto the surface and incubated with the 
biological sample and then with the fluorescence labeled detector antibodies. The 
sample is detected in a fluorescent microscope. This method is more sensitive than the 
reverse-phase [32]. 
 
 
 
Figure 6 Sandwich immunoassay [32]. The capture antibodies are dispensed onto the surface (1), 
followed by blocking and washing steps prior to addition of the biological sample to the chip (2). After 
another wash the chip is incubated with labeled detector antibodies (3) in order to detect the proteins in a 
fluorescent microscope (4). 
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In the context of protein chip technology “Lab-on-a-chip” is a phrase worth noticing. It 
refers to a new technique where the laboratory work can be performed on an 
approximately square centimeter sized chip. The size of the chip means that smaller 
quantities of both analyte and biological sample can be used. This is an advantage in the 
medical sector, where often a limited amount of sample is accessible. There are also 
other positive effects like low fabrication and reagent costs and faster reaction times due 
to the low volumes.  
 
1.5 Surfaces within Protein Chip Technology 
The surfaces or substrates used within the field of protein microarrays require a big 
capacity to bind proteins without changing their functionality and construction. Three 
main groups of surfaces are: passively/physical adsorption, covalent coupling and 
affinity binding [33]. At the department of Electrical Measurements, we produce our 
own in-house developed porous silicon chips for protein chip technology. The porous 
surface enlarges the area offering a vastly increased analytical area. 
 
1.6 Micro- and Nanoporous Silicon  
Around 1957 Turner and Uhlir were the first to observe porous silicon [34, 35]. Since 
then porous silicon has gained interest in numerous applications such as medical therapy 
[36, 37], power technology [38, 39] and optical fibers [40]. As early as in 1996 the T. 
Laurell group produced porous silicon which was used to couple enzymes to the 
extended surface area. [41, 42] In 2002 the porous silicon surface was used as an 
immunoassay support for immobilization of antibodies. The antibodies bound HRP 
(horseradish peroxidase) labeled atrazine, which was detected by chemiluminescence. 
[43] 
 
Anodization is a way to make the silicon chip porous. Silicon atoms can be dissolved 
from the surface in an electrochemical bath under electrostatic bias and/or illumination 
conditions. This is made in an in-house developed chamber as shown in Figure 7. The 
wafer is mounted with a liquid phase containing HF and a solvent on both sides and a 
lamp in front of the window. The charges will move across the bulk silicon and pores 
will form at the surface interface. Those pores will branch and develop nanostructures, 
see  
Figure 8. Figure 8 also describes a possible chemical reaction for dissolution of silicon.  
 
 
Figure 7 In-house developed chamber for anodization of silicon wafers. 
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Figure 8 Chemical pathway of silicon anodization and a schematic drawing of pore formation. Nano-
/macro porous formation are created by migration of the charge in the silicon (A) followed by random 
nucleation (B) and then macropores form and propagate (C) and at last micropores forms branches. [44] 
 
 
An interesting feature of porous silicon surfaces is that creation morphologies can 
display stringly hydrophobic behavior. Normally, when a droplet on a surface 
evaporates it leaves an outer ring of solid material. This phenomenon is called the 
coffee ring effect. [45] As the solvent evaporates from the drop, the contact angle is 
changed. Evaporation is more effective at the peripheral parts of the drop. The 
evaporative losses induce a convective transport inside the droplet outwards to the 
periphery of the droplet. The solid material in the drop is thus transported to the outer 
line where it crystallizes and a coffee ring effect can be seen in Figure 9. [12]  
 
 
Figure 9 Transport flow of the solid particles in a drop [46] 
 
 
The Lotus effect is a phenomenon where a droplet stays on a surface without wetting it. 
The surface behaves hydrophobically and the drop either stays on or rolls off the 
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surface. When the droplet lands on the surface it stays in drop form. The wetting of the 
surface can be more or less hydrophobic, thus the droplet touches the surface with a 
smaller or bigger contact area. This can be measured by the contact angle (θ), see Figure 
10. If the surface is less hydrophobic, the droplet will spread out on the surface and the 
contact angle will be low, sometimes close to 0°. If the surface is more hydrophobic the 
angle can be up to 120° or more. 
 
Figure 10 Contact angle (θ) of a drop on solid material with courtesy of K. Järås, Lunds University. 
 
The surface chemistry of silicon is hydrophilic and proteins on the surface are prevented 
from denaturation as would have been the case on a material with hydrophobic 
chemistry. When the silicon is anodizated the surface will however start to behave 
hydrophobically, corresponding to a high contact angle (θ) and a small contact area 
between the droplet and the chip. This is a clear surface profit within protein chip 
technology, since it increases the signal intensity and leads to improved limit of 
detection. In addition porous silicon chip reduces the coffee ring effect. [44] 
Comparisons have been made by Ressine et al between porous silicon surface and non 
porous glass slides.  
 
1.7 Microdispenser  
To deposit the capture antibody on the surface a spotter, also called arrayer, is required. 
At our department an in-house developed microdispensor is used [47]. The dispenser is 
made from a silicon plate with a nozzle to dispense the droplets. A piezo ceramic plate 
is pushing out the droplets. The dispenser can deposit droplets of approximately 100 pl. 
[47-49]  
 
1.8 Streptavidin Alexa Fluor 488 and FITC-labeled Antibodies 
To detect PSA on porous silicon chips, fluorescently labeled antibodies can be used. In 
this work two different approaches were addressed, one applying biotinylated anti-PSA 
antibodies and Streptavidin (SA) Alexa Fluor 488 conjugate, and the other utilizing 
FITC labeled anti-PSA antibody. Alexa Fluor 488 (Alexa 488) is exited at 495 nm while 
emitting at 519 nm and FITC excites at 494 nm and emits at 519 nm. A 488 nm argon 
laser was used to excite the fluorophores.  
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1.9 Epitope Map 
On the Epitope map as shown in Figure 11 it can be seen which antibodies binds to 
which biomarkers (hK2 and various forms of PSA). To evaluate which monoclonal 
antibodies (mAb) that could be used for the assays in this work, the epitope map was 
studied, see Figure 11.  
 
 
 
Figure 11 Epitope Map of PSA and hK2 showing which antibodies that bind the same epitope. With 
curtsey of Kim Pettersson’s group, University of Turku, Finland [50] 
 
1.10 Aims  
Today in the clinical routine total and to some extent also free PSA are detected in the 
search for prostate cancer. The goal of this project was to try to improve the test in order 
to analyze different biomarkers simultaneously. First a dual approach was tried out, 
where one out of two chips was blocked. PSA free was blocked using unlabeled 
antibodies and the assay approach gave the relative concentrations of PSA total and 
free. In the second step, the multiplex approach, additional biomarkers were added to 
the same chip. The four markers tested were total PSA, free PSA, intact PSA and hK2 
free.  
 
In both steps different capture antibodies were dispensed onto a porous silicon chip in 
order to bind to different biomarkers in the biological sample. The assay was detected 
with a fluorescently labeled detector antibody using a confocal microscope. 
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2. Materials and Methods 
2.1 Materials, Reagents and Proteins  
The Addison Engineering double side polished silicon wafers used were p-type, boron-
doped, with the crystal orientation 100 and resistivity 1-10 Ω cm. Hydrofluoric acid 
(HF), dimethyl formamide (DMF) and dimethyl sulfoxide (DMSO) were obtained from 
Merck.  
 
The 0.01M PBS buffer in powder form with pH 7.4 was bought from Sigma Aldrich. 
Milk powder and casein for blocking were obtained from Bio-Rad and albumin from 
Sigma Aldrich. PBST was made from 0.01M PBS and 0.05% tween 20. The mercoglas 
came from Merck and was provided by Malmö University Hospital (UMAS), 
Department of Pathology. Mouse IgG was obtained from Biodesign and ProStatus PSA 
Assay Buffer originally came from PerkinElmer but was kindly given by the staff at 
Clinical Chemistry, UMAS.  
 
The antibodies H117, 2E9 and 5A10 were kindly given by Malmö University Hospital, 
Clinical Chemistry. The monoclonal antibodies were produced from mice, as earlier 
described. [10] The antibodies 4D4 and 11B6 produced from mice were kindly provided 
by Kim Pettersson’s group at the Department of Biotechnology, University of Tukru, 
Finland. [50, 51] 11B6 F(ab)2 was produced by enzymatic bromelain digestion of 11B6 
mAb. [52] The F(ab)2 fragments had a size of 95-110 kDa in comparison to 150 kDa for 
an intact antibody. 2E9-FITC was labeled in-house [32]. Streptavidin-Alexa 488 (SA-
Alexa 488) was obtained from Invitrogen.  
 
2.2 Samples from the Clinical Routine 
Eight EDTA-plasma samples containing PSA and hK2 were taken from the clinical 
routine at Malmö University Hospital. The female plasma was obtained from a healthy 
volunteer. A titration series of 700, 70, 7 and 0.7 ng PSA tot/ml was made from one of 
the patient samples (original total PSA concentration of 3640 ng/ml) and the female 
plasma.  
 
2.3 Fabrication of Nanoporous Silicon Chip  
The fabrication was performed by anodic dissolution of a p-type, boron-doped silicon 
wafer. The silicon wafer was mounted in a two compartment cell, developed in-house, 
Figure 7. The electrolyte consisted of HF/DMF 1:10. A 100 W halogen lamp was staged 
10 cm from the window of the back chamber. A constant current of 90 mA was applied 
to the wafer. The electrochemical etching took place for approximately 45 min. The 
wafer was diced into pieces sized 0.1380 x 0.1380 inches, equivalent to 3.5 x 3.5 mm, 
by a General Signal Micro Automation 602M saw. 
 
2.4 Dialysis 
The dialysis unit Slide-A-Lyser from Pierce with a molecular weight cut off (MWCO) 
3.5 kDa, was soaked in water before use to remove glycerol from the membrane. To 
change buffer from Tris to PBS and to remove sodium azide (a bacteriostatic 
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preservative) of the antibody suspension the proteins were dialyzed in 500 ml 0.01M 
PBS at 4°C. The buffer solution was changed six times, and thereby the Tris buffer was 
theoretically diluted 75 000 times. 
 
2.5 Biotinylation 
N-Hydroxysuccinimidobiotin from Sigma Aldrich was dissolved in DMSO to the 
concentration of 3.14 mg/ml. The biotin solution was incubated with the antibody H117 
which had the concentration 1.16 mg/ml. The molar ratio between biotin and H117 was 
18.7. The room temperature incubation lasted 4 h and 20 min on end over end rotation. 
The solution was dialyzed (2.4 Dialysis) and the H-Hydroxysuccinimidobiotin was 
theoretically diluted 30100 times.  
 
2.6 Dual Assay 
The dual assay was performed to detect the total as well as the free PSA concentration. 
Half of all the chips were used to detect total PSA. The capture antibody H117 (0.5 
mg/ml) was immobilized by physical adsorption on the silicon chip by the in-house 
developed piezoelectric microdispenser [47]. The volume of a dispensed droplet was 
approximately 100 pl, and the drops were arrayed onto the chip with a distance of 150 
µm. To remove loose bindings the chips were washed three times in 10 ml, 5 ml and 5 
ml PBST respectively, each 5 min on a shaker at room temperature (RT). The chips 
were put in wells of a 96 well plate to separate the reactions and make them easier to 
handle. Blocking was performed by incubating the chips in 5 % milk solution (nonfat 
dry milk diluted in PBST) to reduce unspecific bindings. The microarrays were 
subsequently washed with 150 µl PBST three times, 5 min at RT, 500 rpm. 30 µl of the 
biological sample was incubated on each chip for 60 min at RT, 500 rpm. Washing was 
performed with 150 µl PBST three times, 5 min at RT, 500 rpm. Each chip was 
incubated with 30 µl of the labeled detector antibody (33 µg/ml 2E9-FITC), for 120 min 
in the dark at RT, 500 rpm. The chips were washed with 150 µl PBST three times, 5 
min at RT, 500 rpm, quickly dipped in MQ water and dried with pressurized air. The 
detection was performed in a confocal microscope (Olympus BX51WI) with the 
software Fluoview 300 and the following settings: PMT: 595, gain: 3.1, offset: 0%, 
emission: 510 nm and above, no filter, 20 x objective and 100% laser.  
 
To detect free PSA, a second chip was run in parallel for each plasma sample, using a 
blocking antibody. When the first half of the chips were incubated with 2E9-FITC for 
120 min as described above, the rest of the chips were blocked for the first 60 min with 
0.5 mg/ml antibody 5A10 (free PSA specific antibody) and the last 60 min with 2E9-
FITC. The antibody 5A10 was bound to the free PSA in the biological sample. By 
subtracting the intensity from the chip without 5A10 blocking with the chip blocked 
with 5A10, the signal corresponding to free PSA in the sample could be calculated.  
 
2.7 Multiplex Assay 
The multiplex approach aimed to detect total PSA, free PSA, intact PSA and free hK2 
on the same chip. The capture antibodies 2E9 (0.7 mg/ml), 5A10 (0.7mg/ml), 4D4 (0.6 
mg/ml) and 11B6 (0.6 mg/ml) were immobilized by physical adsorption on the silicon 
chip by the in-house developed chip-based piezoelectric microdispenser [47]. The 
volume of a dispensed droplet was approximately 100 pl, and the drops were arrayed 
 15 
onto the chip with a distance of 150 µm. To remove loose bindings the chips were 
washed three times in 10 ml, 5 ml and 5 ml PBST respectively, each 5 min on shaker at 
room temperature (RT). Each chip was put in a well in a 96 well plate to separate the 
reactions and make it easier to handle. Blocking was performed by incubating the chips 
with 1 % casein or milk in PBS to reduce unspecific bindings. The chips were 
subsequently washed with 150 µl PBST three times, for 5 min at RT, 500 rpm. 30 µl of 
the biological sample was incubated on each chip for 60 min at RT, 500 rpm. Each chip 
was washed with 150 µl PBST three times, 5 min at RT, 500 rpm. Each chip was 
incubated with 30 µl of the detector antibody H117-biotin (5.65 µg/ml) in PBST with 
1% casein, for 60 min at RT, 500 rpm. The microarrays were subsequently washed with 
150 µl PBST three times, 5 min at RT, 500 rpm and then incubated with 30 µl SA-
Alexa 488 (11.3 µg/ml in 0.01M PBS) for 30 min in the dark at RT, 500 rpm. Washing 
was performed with 150 µl PBST three times in the dark, 5 min at RT, 500 rpm. The 
chips were quickly dipped in MQ water and dried with pressurized air. Detection was 
performed in a confocal microscope (Olympus BX51WI) with the same settings in the 
software Fluorview 300 as described in section 2.6. 
 
2.8 Mean Spot Intensity (MSI) and Limit of Detection (LOD) 
Approximately 500 droplets were dispensed per chip. With the 20 x magnification 
roughly 5 x 5 spots could be viewed in the same microscope image. The whole chip was 
visually inspected and two to five images saved. The picture with the highest spot 
intensity was used to quantify the spots. Another criterion that the chosen image had to 
fulfill was a 3 times 3 spot area without air bubbles or scratches. In addition, to each of 
the 3 x 3 spots quantified by the circle method, the background, was measured next to 
the spot. The background area analyzed was the same as the area of the spot. Mean spot 
intensity was based on the nine spot intensities subtracted by the background 
respectively. Standard deviation and coefficient of variation (CV) were calculated for 
each chip.  
 
Limit of detection was defined as the lowest analyte concentration generating a mean 
spot intensity equal to or above MSI of the negative control plus two standard 
deviations based on the measurement of the negative control.  
 
2.9 DELFIA  
ProStatus™ PSA Free/Total DELFIA (Dissociation-Enhanced Lanthanide Fluorescent 
Immunoassay) from PerkinElmer, Turku, Finland was used as a reference assay. [53] 
To detect total and free PSA three antibodies were used in the sandwich assay. H117 
captured both free and bound PSA and two antibodies differently fluorescence-labeled 
were used as detector antibodies. 5A10-Europium recognized free PSA and H50-
Samarium detected total PSA by binding to both free and bound PSA. This method or a 
slightly modified version of it is today utilized in the clinical routine analysis at Malmö 
University Hospital.  
 
To detect PSA intact 5A10 was used as a capture antibody and 4D4 which was 
europium labeled was used as a detector antibody. For free hK2 11B6 was used as a 
capture antibody and 6H10 as the detector antibody.  
 
 16 
3. Results and Discussion 
 
In this thesis four potential prostate cancer biomarkers from the kallikrein family have 
been addressed. Main focus has been assay development, and to show proof-of-concept 
for a multiplex approach on our porous silicon surfaces. Assay development has been 
performed to optimize different factors of the assays. The findings related to assay 
improvements are presented in section 3.1. To bring the thesis closer to a multiplex 
approach the first step was a dual assay performed on two chips, where PSA total and 
free were measured. In paragraph 3.2 the dual assay results from eight EDTA plasma 
samples obtained from patients undergoing clinical PSA testing are presented. The 
second step was to detect various biomarkers on one porous silicon chip, the so called 
multiplex approach. Separate titration series of the four biomarkers as well as a final 
proof-of-principle detection of several biomarkers on the same chip are shown in 
section 3.3. 
 
3.1 Assay Development 
In order to get the laboratory work optimized a number of factors needed to be 
evaluated, such as dispenser and etching, blocking, background and spot focus.  
 
3.1.1 Dispenser and Etching 
When the antibodies were dispensed onto the porous silicon chips it was important to 
achieve homogeneous droplet formation without satellite effects. Homogeneous droplet 
formation is a prerequisite for adequate spot detection and comparison of signal 
intensity between the chips. The first chip batch produced gave rise to very high 
hydrophobicity of the surfaces. During dispensing the droplets bounced away from the 
porous silicon layer of approximately every second chip. The superhydrophobic chips 
had to be replaced by less hydrophobic ones from the same batch. In the second chip 
batch produced, the etching time was reduced to 40 minutes and the surfaces were 
slightly less hydrophobic and therefore gave no bouncing effect. The hydrophobicity did 
not only depend on the etching time but also on the resistivity of the chip batch in 
question.  
 
The satellite effect shown in Figure 12 could be avoided by changing the voltage over 
the dispenser. The optimal settings were approximately 4 V on the Frequency Generator 
and 15 V on the Voltage Regulator.  
 
 
 
Figure 12 Satellite effect. Small unwanted droplets between the dispensed droplets.   
 17 
 
3.1.2 Blocking 
To avoid unspecific binding of the antibodies, blocking was performed after dispensing 
the capture antibody. Three different blocking agents were tested: 5% milk, 1% casein 
and 5% albumin. The assay was performed as described in section 2.7. The total PSA 
concentration was analyzed for one of the EDTA-plasma samples (31.1 ng PSA 
total/ml). The data for each blocking agent was based on two chips treated equally. On 
each chip two images were selected and on each image the background were measured 
three times. The background area was based on a square with the following dimensions: 
x= 400µm, y=50µm.  
 
In Table 1 the mean of the background intensities are shown for the blocking agents 
milk, casein and albumin. Casein had the lowest mean and in addition the lowest CV 
and had thereby blocked the most. Milk was the second best alternative but was 
delivered in powder form and sometimes harder to prepare because it was not 
solubilised as the casein. Casein was used as an easy and good blocking agent in the rest 
of the assays described in this thesis.  
 
Table 1: Background intensity results for blocking optimization. 
Chip 
Background  
Intensity  
CV 
n=12 
Milk 7.6·10
6
 0.20 
Casein 7.2·10
6
 0.05 
Albumin 9.9·10
6
 0.16 
 
3.1.3 Background  
In order to avoid background intensity caused by salt formation of the buffer the chips 
were dipped in MQ water for five seconds and dried with pressurized air. Even though 
this was a procedure used previously, an optimization was made and two other methods 
were tried out. The first was to not dip the chip into MQ water but dry with pressurized 
air. The second technique was to neither dip the chip into MQ water nor dry with 
pressurized air, instead directly measure in the microscope. The background 
optimization was mainly developed for the intact PSA assay with the antibody 4D4, an 
antibody sensitive to washing. By evaluating the background using 4D4 it is made sure 
that the quick dip in water does not reduce the spot intensity. The EDTA-plasma from 
the clinical routine with concentration 31.1 ng PSA total/ml was used in the analysis. 
 
The different methods gave high spot intensity on all three chips. The results for the 
MSI and the background measurements can be seen in Table 2. The background was 
measured the same way as in 3.1.2 except that only one chip per method was performed. 
As anticipated the chip dipped in MQ water and dried had the lowest background value, 
see Table 2. The chip which was only dried had a high homogenous background and the 
chip directly measured had a more heterogeneous and stained background. The method 
with the lowest background had unfortunately slightly lower MSI but the low 
background value was to prioritize to not jeopardize the LOD. 
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Table 2 Results for background minimization using the three different dipping and drying procedures. 
Method  MSI 
CV 
n=9 
Background 
intensity 
CV 
n=6 
MQ + dry 18.0·10
6
 0.07 4.3·10
6
 0.09 
dry 18.5·10
6
 0.08 8.9·10
6
 0.12 
nothing 18.8·10
6
 0.14 9.5·10
6
 0.41 
 
3.1.4 Spot Focus  
Microscopic measurements were performed with oil immersion. A drop of MQ water 
was placed on the chip under the cover glass prior to detection. The cover glass must lie 
flat to bring focus on nine spots simultaneously. Difficulties arose when lifting the cover 
glass to place it parallel to the small chip beneath. In addition the intensity is reduced 
when lifting the glass extensively, therefore two lifts were considered maximum. 
Instead of MQ water Mercoglas was tried under the cover glass.  
 
Mercoglas was a poor option since it is a polymer reflecting light from the laser and 
made the whole chip glow. Instead of Mercoglas MQ water was used in an in-house 
produced Plexiglas slide with an indentation for a chip. This arrangement prevented the 
cover glass from tilting as much and the focus could be brought to nine spots or more 
simultaneously. The only reason to lift the cover glass with this method is to get rid of 
air bubbles which maximally takes two lifts.  
 
3.2 Dual Assay 
On the way towards a multiplex approach the dual assay was developed. This assay, in 
which PSA total and free are detected, is based on two chips (Figure 13). The same 
capture and detector antibodies, H117 and 2E9-FITC respectively, are used in both 
microarrays. On one of the chips the signal of PSA free is blocked by addition of the 
antibody 5A10. The mean spot intensity for PSA total is measured on the first chip. The 
MSI of PSA free is calculated as the MSI difference between the first and the second 
chip.  
 
 
 
Figure 13 Dual assay procedure. Two chips (upper and lower row respectively) are used simultaneously. 
On the lower one the PSA free is blocked before detection. The chips are first dispensed with capture 
antibody H117 (1) followed by washing and blocking steps. Then the lower chip is blocked against PSA 
free with antibody 5A10 (3 lower) and subsequently incubated with the FITC labeled detector antibody 
2E9 (3 upper and 4 lower). The last step, after yet another washing, is the fluorescent readout. The upper 
chip generates the total PSA signals, and signal intensities of upper chip minus lower is proportional to 
the PSA free concentration.  
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The dual assay approach was evaluated with eight EDTA-plasma samples from the 
clinical routine. All samples were diluted to get a final concentration of 10-20 ng/ml in 
the dual assay. Table 3 shows the results from the DELFIA and microarray 
measurements. CV was calculated based on 9 adjacent array spots. The results are also 
visualized in the graph of Figure 14, in which mean spot intensity is plotted against PSA 
concentration as measured by the DELFIA. Note that both MSI of PSA tot and PSA 
free are plotted against total PSA concentration by the DELFIA. In this way the results 
of free and total PSA are shown beneath each other, indicating that they belong to the 
same analysis. In all of the eight plasma samples except for sample number two, the 
mean spot intensity was higher for PSA total compared to the blocked chips, thereby 
establishing a successful shielding by 5A10 antibodies.  
 
Table 3 Dual assay. DELFIA and MSI results with CV for total and free PSA 
Sample  
PSA total PSA free 
DELFIA  
(ng/ml) MSI* 
CV  
n=9 
DELFIA 
(ng/ml) MSI* 
CV  
n=9 
1 3640 7500·10
6
 0.08 329 3100·10
6
 0.20 
2 2260 770·10
6
 0.11 326 -16·10
6
 -6.40 
3 907 400·10
6
 0.18 152 200·10
6
 0.34 
4 88.5 38·10
6
 0.26 31.3 9.7·10
6
 0.87 
5 85.7 82·10
6
 0.16 12.4 52·10
6
 0.25 
6 80.7 82·10
6
 0.11 10.9 32·10
6
 0.31 
7 31.1 5.6·10
6
 0.09 8.52 2.8·10
6
 0.22 
8 20.3 3.8·10
6
 0.09 4.02 0.94·10
6
 0.46 
* The measured MSI was multiplied with the dilution factor generating the MSI presented in the table.  
 
In sample number two the cover glass on the PSA total chip was lifted more than twice 
to adjust it horizontally and by that the PSA free value got negative. This experiment 
was performed before the glass slide with the indentation was used. In Figure 14 the 
free PSA value is missing because it is not possible to logarithm a negative value.  
 
All samples, except for number two and four, decreased successively in MSI with 
decreasing total PSA concentration as measured by DELFIA. The MSI for PSA total 
and free on sample number four had lower intensities and the corresponding CVs were 
raised. This could have been caused by a number of things, such as moving cover glass 
extensively, laboratory errors or possibly dilution errors. The same titration pattern 
appeared with PSA free but here also a divergent value on sample number two was 
present.  
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Figure 14 MSI results for total and free PSA with standard deviations are plotted against the DELFIA 
results for total PSA. Note that both axes are logarithmic. 
 
In the future the aim is to make a true quantitative approach to measure total and free 
PSA in a dual assay. This requires a standard curve which is run together with the 
plasma samples to be analyzed. Since the MSI of the total and free PSA measurements 
are clearly separated from each other the possibility of developing a true quantitative 
dual assay seems reasonably high. 
 
3.3 Multiplex Assay  
The aim of the multiplex assay was to detect four different biomarkers on one porous 
silicon chip simultaneously as shown in Figure 15. To achieve the goal the antibody 
couples for total PSA, free PSA, intact PSA and free hK2, see Table 4, were evaluated 
one by one before a possible combination on the same chip. With use of the Epitope 
Map, see Figure 11, the capture antibodies in Table 4 were selected. To detect all 
biomarkers simultaneously on one chip the detector antibody should preferably be the 
same. The detector antibody was biotinylated and coupled to Streptavidin-Alexa 488 to 
be detected in the confocal microscope.  
 
 
 
 
Figure 15 Fourplex assay. The four different capture antibodies (2E9, 5A10, 4D4 and 11B6) are arrayed 
onto the chip (1). After a blocking step and washing the biological sample is added (2), different forms of 
PSA and hK2 bind to their specific antibodies. The detector antibody H117-biotin and streptavidin-Alexa-
488 are added (3) and then detected in the fluorescent microscope (4).  
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Table 4 Capture and detector antibody couples used in the assays 
Biomarker Capture ab Detector ab 
PSA total 2E9 H117 
PSA free 5A10 H117 
PSA intact 4D4 H117 
hK2 free 11B6 F(ab)2/mAb H117 
 
3.3.1 Total PSA 
Total PSA was analyzed by capture antibody 2E9 and detector antibody H117 as 
illustrated in Figure 16. H117 was biotinylated and coupled to SA-Alexa 488. In Figure 
17 the MSI for total PSA in the dilutions series ranging from 0.7 to 700 ng/ml PSA total 
is plotted against the results of the reference assay. The mean spot intensity increased 
with increasing PSA concentration as measured by the DELFIA. The MSI of the highest 
PSA concentration was not linear with the other three MSI values plotted. The reason is 
the exceptionally high analyte concentration above the upper detection limit of the 
confocal microscope. As a control female plasma was analyzed and no signals could be 
detected (data not shown). LOD of the assay was 0.7 ng/ml.   
 
 
Figure 16 Total PSA detection. Dispensing of capture antibody 2E9 (1) and incubation of the biological 
sample (2) before detection by the detector antibody H117-biotin coupled to streptavidin-Alexa-488 (3) in 
the fluorescent microscope (4). 
 
 
Figure 17 MSI results of total PSA assay plotted against DELFIA values from UMAS. The error bars 
represent the standard deviations calculated from nine inset images.  
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3.3.2 Free PSA  
Free PSA was analyzed by capture antibody 5A10 and detector antibody H117-biotin, 
which was coupled to SA-Alexa 488 to be detected (Figure 18). In Figure 19 the results 
from the dilutions series 0.7-700 ng/ml total PSA is shown. The x-axis displays the 
DELFIA results and the y-axis the MSI with standard deviations included. The MSI 
increased with the increasing DELFIA values as shown in Figure 19. The DELFIA 
result for the lowest concentration was 0.05 ng/ml. This concentration seemed to be 
below detection limit of our microarray and could unfortunately not be detected. As a 
control sample female plasma was analyzed and no signals could be detected (data not 
shown). Limit of detection for the assay was 4.7 ng/ml. Spots were visible on the 
concentration for 0.5 ng/ml see Figure 19, but the high background generated an 
unfavorable limit of detection.  
 
 
Figure 18 Free PSA detection. The detector antibody 5A10 was spotted onto the chip (1) followed by 
incubation of the biological sample (2) and at last detection by fluorescently labeled (streptavidin-Alexa-
488) detector antibody H117-biotin (3) in the microscope (4). 
 
 
 
Figure 19 MSI results plotted against DELFIA values for PSA free. Standard deviations were calculated 
from the nine inset images.  
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3.3.3 Intact PSA 
Intact PSA was captured with the antibody 4D4 and detected with the antibody H117-
biotin and SA-Alexa 488 as illustrated in Figure 20. As shown in Figure 20, intact PSA 
was difficult to detect straightforward with the antibodies selected. The titration series 
with PSA total concentration of 0.7-700 ng/ml gave rise to low signals and no 
differences in MSI for the four plasma samples, see Figure 21. The MSI was only based 
on 1-3 spots and thereby no standard deviations are shown. On one of the chips only 2 
out of approximately 500 spots were visible. The two lowest PSA intact concentrations 
in the titration series were not detectable by the DELFIA either. 
 
It turned out that the antibody 4D4 had a high koff and thereby probably the antigen 
dissociated from the antibody in the many washing steps. By incubating without 
washing after addition of the biological sample the bindings were maintained. Only one 
washing step before detection and the quick dip in MQ water were kept. This 
improvement gave rise to a higher signal (data not shown). To make sure that the quick 
dip in MQ water did not affect the binding of PSA the background optimization as 
described in 3.1.3 was performed with 4D4 analyzing intact PSA.  
 
 
Figure 20 PSA intact detection. Spotting of capture antibody (1) subsequent incubation with biological 
sample (2) detection with SA-Alexa 488 and detector antibody H117-biotin (3) in the confocal 
microscope (4) are performed. 
 
 
 
Figure 21 PSA intact results. MSI measurements plotted against DELFIA assay concentrations. 
 
 24 
3.3.4 hK2 free 
To detect hK2 free both 11B6 F(ab)2 and 11B6 mAb were tested as capture antibodies 
and H117-biotin-SA-Alexa 488 was used for detection (Figure 22). The titration series 
with PSA total concentrations of 0.7-700 ng/ml was used together with a negative 
control consisting of female plasma.  
 
The DELFIA could not measure any hK2 in the two biological samples with lowest 
hK2 concentrations, since the concentration was below the LOD of the assay. All of the 
microarrays had extremely high mean spot intensity with F(ab)2 as capture antibody, see 
Figure 23. Even the negative control sample was extremely high (data not shown). The 
MSI was based on only 1-3 spots therefore no standard deviations could be calculated. 
Using monoclonal antibodies as capture molecule gave similar result. The antibodies 
had been frozen prior to use but have proved to perform well in other situations. The 
assay was later run with both PSA Assay Buffer and mouse IgG to remove heterophilic 
antibodies, i.e. antibodies binding to the Fc region, and human-α-mouse-antibody 
respectively. Neither of those methods got rid of the false signal. It should be noted that 
only one female plasma donor was tried out, and that both the negative control as well 
as the titration series (0.7-700 ng/ml tot PSA) contained this female plasma.  
 
 
 
Figure 22 Free hK2 detection. The capture antibody 11B6 was dispensed onto the porous silicon chip (1) 
and then incubated with the biological sample containing hK2 (2). Detector antibody H117-biotin and 
streptavidin-Alexa-488 (3) were used to measure the intensity in the fluorescence readout system (4). 
 
 
 
Figure 23 hK2 free results for the MSI measurements plotted against the DELFIA reference assay. 
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3.3.5 Triplex 
Three of the four potential antibody couples generated promising results according to 
the data presented above. hK2 needs to be evaluated more before usage in a multiplex 
approach. PSA total, free and intact were now put together to a multiplex approach. The 
capture antibodies 2E9, 5A10 and 4D4 for PSA total, free and intact respectively were 
dispensed on the same chip as shown in Figure 24. The titration series with the 
concentration of 0.7-700 ng/ml PSA total and a negative control were added to five 
different chips. Only one washing step and the quick dip in MQ water was performed 
after the biological sample was added, due to PSA intact, as described in 3.3.3. 
 
 
 
Figure 24 Triplex spotting design on the chips sized 3.5 x 3.5 mm. 
 
All three biomarkers were successfully detected in the fluorescence microscope for all 
concentrations in the dilution series except the lowest concentration for PSA free, as 
shown in Table 5 and Figure 25. The triplex assay gave three increasing titration curves 
with increasing DELFIA values, see Figure 26. The different PSA forms are all plotted 
against the DELFIA value for the PSA total concentration. In this way the results of 
total, free and intact PSA are shown beneath each other, indicating that they belong to 
the same analysis. The intensity corresponding to a PSA total concentration of 700 
ng/ml was so high that it superseded the detector in the confocal microscope. The two 
highest concentrations 70 and 700 ng/ml got similar values even though a clear 
difference could be seen by visual inspections of the screen. Since the background 
intensity, rising with analyte concentration, did not reach the top altitude it subtracts the 
intensity value of the 700 ng/ml substantially generating a lower MSI than the 
concentration of 70 ng/ml. Therefore artifacts with decreased intensities at the highest 
analyte concentrations are present in Figure 26. 
 
 
Table 5 Triplex assay. DELFIA and MSI results with CV for total, free and intact PSA 
 PSA total PSA free PSA intact 
DELFIA 
(ng/ml) 
MSI CV DELFIA MSI CV DELFIA 
(ng/ml) 
MSI CV 
0.7 630 0.46·10
6
 0.21 57 0.45·10
6
 0.30 36 0.62·10
6
 0.12 
7 66 5.1·10
6
 0.25 4.7 1.8·10
6
 0.31 3.1 1.4·10
6
 0.29 
70 6.3 15·10
6
 0.04 0.47 37·10
6
 0.04 - 14·10
6
 0.10 
700 0.76 12·10
6
 0.18 0.05 21·10
6
 0.19 - 17·10
6
 0.07 
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Figure 25 Images from the fluorescence microscope of PSA total, free and intact at the different PSA 
concentrations. A-images represent the negative control and B-E are the dilution series 0.7-700 ng PSA 
total/ml. At the images E the concentration are over the upper LOD of the samples.  
 
 
 
 
 
Figure 26 Triplex results. MSI plotted against DELFIA results. The values in origo represent the negative 
female plasma.  
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Unfortunately a low signal was detected from the negative control (female plasma) on 
PSA intact and PSA total. This probably has to do with the fact that many of the 
washing steps were removed due to the high kOff of 4D4. If 4D4 can bind to PSA intact 
even though a slightly more stringent washing is performed the faint signals of the 
negative controls could probably be washed away.  
 
The lowest analyte concentrations in the dilution series for PSA total and intact and the 
second lowest for PSA free could successfully be detected (Table 6). LODs for the 
different PSA forms in the triplex assay can be seen in Table 6. It should be noted that 
LOD for PSA intact is as low as 0.03ng/ml. In addition the analyte concentrations could 
possibly be titrated a bit further to improve the LODs even more. It is likely that the 
LODs could be improved in this thesis compared to earlier work at the department, 
since there is a possible signal amplification effect, due to the biotinylation of H117. 
The more biotin coupled to the detector antibody, the more streptavidin-Alexa 488 
could be bound and the signal will be amplified.  
 
 
Table 6 LOD for PSA total, free and intact in the triplex assay 
 LOD (ng/ml) 
PSA total 0.8 
PSA free 0.5 
PSA intact 0.03 
 
 28 
4. Conclusions and Further Research  
 
The detection of PSA as well as other PCa biomarkers can be scaled down on 
microarrays and used in the clinical diagnostics and prognostics. The miniaturized 
technique entails lower consumption of biological samples as well as reagents. Järås et 
al made a study in 2007 [32] on different miniaturized microarray techniques on 3D 
porous silicon chip and concluded that sandwich assays are the best choice. Because 
PSA not only codes for prostate cancer but also for example BPH, various markers need 
to be addressed to achieve a better screening for prostate cancer. In this thesis the first 
steps towards a multiplex sandwich approach has successfully been demonstrated. The 
first goal, to make a dual assay to measure PSA total and free was accomplished. In the 
future this assay aims to make a true quantitative approach to measure PSA total and 
PSA free. The second aim of the thesis, to show proof-of-principle of a multiplex 
approach, was also fulfilled. Three different forms of PSA were measured 
simultaneously on one porous silicon chip. Further optimization needs to be done 
regarding the washing steps. The assay for hK2 needs to be investigated in detail in 
order to try to extend the microarray from a triplex to a fourplex assay. In the future 
other suitable biomarkers connected to prostate cancer can be tried out and added to the 
multiplex assay. 
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5. Populärvetenskaplig sammanfattning på svenska 
 
Prostatacancer är den vanligaste formen av cancer för män i väst-världen. Sjukdomen är 
åldersrelaterad och tre fjärdedelar av de drabbade är 65 år eller äldre. För att 
diagnostisera prostatacancer kan en markör i blodet mätas. Denna markör, kallad 
prostataspecifikt antigen (PSA), uttrycks i större mängd i blodet vid 
prostataförändringar. För att kunna hitta prostatacancer och skilja sjukdomen från bland 
annat godartad prostataförstoring skulle fler markörer kunna detekteras samtidigt.  
 
Inom vården idag mäts nivåerna av den totala mängden PSA och ibland även fritt PSA. 
Fritt PSA är en del av den totala mängden PSA och består av PSA som inte är bundet 
till något annat protein. Mätningarna idag skiljer inte tillfredställande på godartat 
prostataförstoring och prostatacancer vilket behöver förbättras. I detta examensarbete 
har fyra markörer, även kallade analyter, undersökts i ett miniatyriserat format. De fyra 
markörerna som undersöktes var förutom totalt och fritt PSA, intakt PSA, vilket hittas i 
både det fria och bundna formerna av PSA, samt humant kallikrein 2 (hK2) som till hör 
samma familj som PSA.  
 
För att mäta koncentrationen av en sorts analyt i blodet användes två olika antikroppar. 
Markörerna i blodprovet fångades upp med hjälp av antikroppar som var fästa på ett 
poröst kiselchip med storleken 3,5 gånger 3,5 mm likt bilden nedan. Kiselchipen utgör 
en bra fästyta och är egenutvecklade. För att detektera hur många analyter som fastnat 
på antikropparna användes en annan antikropp som var fluorescensmärkt, och således 
kunde mängden markörer mätas i ett fluorescensmikroskop.  
 
 
 
 
 
För att kunna fånga upp de olika markörerna på ett och samma chip behövs olika 
antikroppar, var och en specifik mot enbart en av analyterna. För att detektera de 
bundna biomarkörerna behövs en annan antikropp som har bindningsförmåga till alla 
markörerna och som är märkt med en, i ett mikroskop lysande, molekyl. Var och en 
utav dessa antikroppspar med tillhörande biomarkör testades för sig innan de 
sammanförandes på ett enda chip.  
 
Det visade sig att antikroppsparet för hK2 inte fungerade tillfredställande och måste 
utvärderas mer innan det går att använda. De tre andra antikroppsparen för markörerna 
totalt PSA, fritt PSA och intakt PSA fungerade efter olika optimeringar bra och kunde 
således samtidigt mätas på samma chip i en såkallad triplex modell.  
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